CRL
$232.56
Revenue | $1013.48Mn |
Net Profits | $187.08Mn |
Net Profit Margins | 18.46% |
Charles River Laboratories International’s revenue fell -7.85% since last year same period to $1013.48Mn in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated -1.28% fall in its revenue since last 3-months.
Charles River Laboratories International’s net profit fell -0.17% since last year same period to $187.08Mn in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated 114.08% jump in its net profits since last 3-months.
Charles River Laboratories International’s net profit margin jumped 8.33% since last year same period to 18.46% in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated 116.86% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 2.07 |
EPS Estimate Current Year | 2.07 |
Charles River Laboratories International’s earning per share (EPS) estimates for the current quarter stand at 2.07 - a -13.75% fall from last quarter’s estimates.
Charles River Laboratories International’s earning per share (EPS) estimates for the current year stand at 2.07.
Earning Per Share (EPS) | 2.46 |
Charles River Laboratories International’s earning per share (EPS) fell -17.45% since last year same period to 2.46 in the Q4 2023. This indicates that the Charles River Laboratories International has generated -17.45% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-05-11 | 2.59 | 2.78 | 7.34% |
2023-08-09 | 2.64 | 2.69 | 1.89% |
2024-02-14 | 2.4 | 2.46 | 2.5% |
2023-11-08 | 2.37 | 2.72 | 14.77% |